180 related articles for article (PubMed ID: 20713850)
61. Characteristics and outcomes of rhabdomyosarcoma patients with isolated lung metastases from IRS-IV.
Rodeberg D; Arndt C; Breneman J; Lyden E; Donaldson S; Paidas C; Andrassy R; Meyer W; Wiener E
J Pediatr Surg; 2005 Jan; 40(1):256-62. PubMed ID: 15868594
[TBL] [Abstract][Full Text] [Related]
62. Conservative management of uterine pediatric rhabdomyosarcoma: a report from the Intergroup Rhabdomyosarcoma Study III and IV pilot.
Corpron CA; Andrassy RJ; Hays DM; Raney RB; Wiener ES; Lawrence W; Lobe TE; Maurer HM
J Pediatr Surg; 1995 Jul; 30(7):942-4. PubMed ID: 7472949
[TBL] [Abstract][Full Text] [Related]
63. Proton radiotherapy for parameningeal rhabdomyosarcoma: clinical outcomes and late effects.
Childs SK; Kozak KR; Friedmann AM; Yeap BY; Adams J; MacDonald SM; Liebsch NJ; Tarbell NJ; Yock TI
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):635-42. PubMed ID: 21377294
[TBL] [Abstract][Full Text] [Related]
64. The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children's Oncology Group.
Malempati S; Weigel BJ; Chi YY; Tian J; Anderson JR; Parham DM; Teot LA; Rodeberg DA; Yock TI; Shulkin BL; Spunt SL; Meyer WH; Hawkins DS
Cancer; 2019 Jan; 125(2):290-297. PubMed ID: 30351457
[TBL] [Abstract][Full Text] [Related]
65. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma--a report from the Intergroup Rhabdomyosarcoma Study IV.
Breneman JC; Lyden E; Pappo AS; Link MP; Anderson JR; Parham DM; Qualman SJ; Wharam MD; Donaldson SS; Maurer HM; Meyer WH; Baker KS; Paidas CN; Crist WM
J Clin Oncol; 2003 Jan; 21(1):78-84. PubMed ID: 12506174
[TBL] [Abstract][Full Text] [Related]
66. Benefit of delayed primary excision in rhabdomyosarcoma: A report from the Children's Oncology Group.
Lautz TB; Chi YY; Li M; Wolden SL; Casey DL; Routh JC; Granberg CF; Binite O; Rudzinski ER; Hawkins DS; Venkatramani R; Rodeberg DA
Cancer; 2021 Jan; 127(2):275-283. PubMed ID: 33079399
[TBL] [Abstract][Full Text] [Related]
67. Parameningeal rhabdomyosarcoma: results of an international workshop.
Benk V; Rodary C; Donaldson SS; Flamant F; Maurer H; Treuner I; Carli M; Gehan E
Int J Radiat Oncol Biol Phys; 1996 Oct; 36(3):533-40. PubMed ID: 8948336
[TBL] [Abstract][Full Text] [Related]
68. 45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Ermoian RP; Breneman J; Walterhouse DO; Chi YY; Meza J; Anderson J; Hawkins DS; Hayes-Jordan AA; Parham DM; Yock TI; Donaldson SS; Wolden SL
Pediatr Blood Cancer; 2017 Sep; 64(9):. PubMed ID: 28548706
[TBL] [Abstract][Full Text] [Related]
69. Age is a risk factor for chemotherapy-induced hepatopathy with vincristine, dactinomycin, and cyclophosphamide.
Arndt C; Hawkins D; Anderson JR; Breitfeld P; Womer R; Meyer W
J Clin Oncol; 2004 May; 22(10):1894-901. PubMed ID: 15143082
[TBL] [Abstract][Full Text] [Related]
70. Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee.
Cecchetto G; Carretto E; Bisogno G; Dall'Igna P; Ferrari A; Scarzello G; Donfrancesco A; Alaggio R; Indolfi P; Carli M
Pediatr Blood Cancer; 2008 Nov; 51(5):593-7. PubMed ID: 18668515
[TBL] [Abstract][Full Text] [Related]
71. Prognostic relevance of early radiologic response to induction chemotherapy in pediatric rhabdomyosarcoma: A report from the International Society of Pediatric Oncology Malignant Mesenchymal Tumor 95 study.
Vaarwerk B; van der Lee JH; Breunis WB; Orbach D; Chisholm JC; Cozic N; Jenney M; van Rijn RR; McHugh K; Gallego S; Glosli H; Devalck C; Gaze MN; Kelsey A; Bergeron C; Stevens MCG; Oberlin O; Minard-Colin V; Merks JHM
Cancer; 2018 Mar; 124(5):1016-1024. PubMed ID: 29211298
[TBL] [Abstract][Full Text] [Related]
72. Parameningeal rhabdomyosarcoma: outcomes and opportunities.
Yang JC; Wexler LH; Meyers PA; Wolden SL
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e61-6. PubMed ID: 23021437
[TBL] [Abstract][Full Text] [Related]
73. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group.
Pappo AS; Anderson JR; Crist WM; Wharam MD; Breitfeld PP; Hawkins D; Raney RB; Womer RB; Parham DM; Qualman SJ; Grier HE
J Clin Oncol; 1999 Nov; 17(11):3487-93. PubMed ID: 10550146
[TBL] [Abstract][Full Text] [Related]
74. A phase II trial evaluating selective use of altered radiation dose and fractionation in patients with unresectable rhabdomyosarcoma.
Regine WF; Fontanesi J; Kumar P; Zeitzer K; Greenwald C; Bowman L; Shapiro DN; Rao BN; Kun LE
Int J Radiat Oncol Biol Phys; 1995 Feb; 31(4):799-805. PubMed ID: 7860391
[TBL] [Abstract][Full Text] [Related]
75. Controversies in the management of paratesticular rhabdomyosarcoma: is staging retroperitoneal lymph node dissection necessary for adolescents with resected paratesticular rhabdomyosarcoma?
Wiener ES; Anderson JR; Ojimba JI; Lobe TE; Paidas C; Andrassy RJ; Raney RB; Qualman SJ; Donaldson SS; Maurer HM; Link MP; Crist WM; Grier HE
Semin Pediatr Surg; 2001 Aug; 10(3):146-52. PubMed ID: 11481652
[TBL] [Abstract][Full Text] [Related]
76. Preliminary results of a phase II trial of proton radiotherapy for pediatric rhabdomyosarcoma.
Ladra MM; Szymonifka JD; Mahajan A; Friedmann AM; Yong Yeap B; Goebel CP; MacDonald SM; Grosshans DR; Rodriguez-Galindo C; Marcus KJ; Tarbell NJ; Yock TI
J Clin Oncol; 2014 Nov; 32(33):3762-70. PubMed ID: 25332253
[TBL] [Abstract][Full Text] [Related]
77. Local Treatment of Children Suffering From Parameningeal Rhabdomyosarcoma: A Retrospective Single-Center Study From China.
Peng X; Xiong X; Li Y; Li C; Wang Z; Wu Y; Su M; Weng W; Huang K; Zhou D; Fang J
Cancer Control; 2024; 31():10732748241240655. PubMed ID: 38514935
[TBL] [Abstract][Full Text] [Related]
78. Age is an independent prognostic factor in rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
Joshi D; Anderson JR; Paidas C; Breneman J; Parham DM; Crist W;
Pediatr Blood Cancer; 2004 Jan; 42(1):64-73. PubMed ID: 14752797
[TBL] [Abstract][Full Text] [Related]
79. Radiation therapy target volume reduction in pediatric rhabdomyosarcoma: implications for patterns of disease recurrence and overall survival.
Eaton BR; McDonald MW; Kim S; Marcus RB; Sutter AL; Chen Z; Esiashvili N
Cancer; 2013 Apr; 119(8):1578-85. PubMed ID: 23280478
[TBL] [Abstract][Full Text] [Related]
80. Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
